iCAD, Inc. will present their most-recent clinical results in cancer patients’ outcomes using theirs newest Xoft® Axxent® Electronic Brachytherapy (eBx®) System®. The presentation will take place at the 56th Annual American Society for Therapeutic Radiology and Oncology (ASTRO) meeting, September 14-17, 2014 at the Moscone Center in San Francisco.
iCAD is an industry-leading provider in technology development for early detection and treatment of cancer. It provides services in advanced image analysis, workflow solutions, and radiation therapy.
Electronic brachytherapy (eBx) is a new method of delivering radiation therapy. The Xoft eBx System does not use radioactive isotopes, nor does it require heavy shielding or major capital equipment investment.
Ken Ferry, President and CEO of iCAD noted in a PR Newswire press release, “This is a very exciting year for iCAD as we have significantly expanded our position as the industry’s leading comprehensive solution provider in eBx. We look forward to outlining the elements of our new solutions and services and to giving customers a hands-on experience with our recent advances to the technology platforms, including the debut of our Axxent SPX Controller, the latest extension of the Xoft System product line. With our progress this year, iCAD is uniquely positioned to provide significant technology and service advantages to our valued customers and their patients.”
“We continue to be encouraged by the positive data presented on the Xoft System for the treatment of non-melanoma skin cancer, as it further demonstrates the System’s distinct clinical and cosmetic advantages,” added Mr. Ferry in the same press release.
iCAD Technology Updates and Demonstrations
iCAD will present the new Axxent SPX Controller featuring a brand new design developed specifically for clinical practices providing surface eBx treatments. Its improvements include the ability to work in smaller treatment rooms, extended options for patient positioning and improved access to difficult locations of treatment. A bar coding system improving workflow efficiency and HIPAA compliance was also added.
The new features were included on the multi-platform Axxent MPX Controller, the company’s commercial platform product approved for use in all cancer treatments, including breast IORT, breast APBI, skin, endometrial and cervical cancer.
Rakesh Patel, M.D., Medical Director at The Targeted Radiation Institutes in the East and South Bay Areas, CA explained in the press release, “Electronic brachytherapy allows radiation oncologists to expand the reach of HDR brachytherapy beyond conventional shielded vaults. It inherently offers safety for patients and personnel, target flexibility for challenging anatomic areas and fine radiation dose control. The new streamlined design may be easier to integrate into smaller spaces in many clinical facilities.”
iCAD will showcase at the ASTRO meeting the new innovations of the Axxent MPX Controller and Axxent SPX Controller, and will also preform demonstrations of iCADs’ recent acquisitions DermEbx and Radion.
iCAD invites ASTRO attendees to visit the booth for personal demonstrations on the new technologies or for any additional information.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?